Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A clinical-stage life science company developing Gemini, a proprietary TLR4 agonist formulation. Current product candidates include GEM-AKI (acute kidney injury) and GEM-CKD (chronic kidney disease). The company has no commercial revenue and relies on capital raises to fund operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6,332,435) | $(4,495,467) |
| Net Loss Attributable to Common Stockholders | $(12,014,051) | $(7,677,253) |
| Operating Expenses | $6,754,741 | $4,556,216 |
| Cash and Cash Equivalents (End of Period) | $11,482,792 | $5,173,871 |
| Net Cash Used in Operating Activities | $(5,772,044) | $(4,713,688) |
| Net Cash Provided by Financing Activities | $6,666,012 | $3,388,541 |
| Total Assets | $12,497,932 | $11,582,924 |
| Accumulated Deficit | $(55,751,722) | $(49,419,287) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose by $2.2 million (48%) year-over-year, driven by a $1.1 million increase in R&D and a $1.1 million increase in G&A. R&D growth was primarily due to GEM-AKI program and manufacturing costs.
- Capital Raises: The company raised approximately $6.7 million in net proceeds during the six months ended June 30, 2026, primarily through the Class I Warrant Inducement. This contrasts with $3.4 million raised in the same period in 2025.
- Deemed Dividends: A significant non-cash charge of approximately $5.7 million was recorded as a deemed dividend due to the reset of exercise prices on various warrant classes (Class D, G, H, and I) triggered by the Class I Warrant Inducement. This significantly increased the net loss attributable to common stockholders.
- Reverse Stock Splits: The company effected a 1-for-4 reverse stock split on January 28, 2026, adjusting share counts and per-share metrics.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management states that current cash resources ($11.5 million) are insufficient to sustain operations for one year from the filing date. The company expects to continue incurring significant losses and requires additional financing to continue as a going concern.
- Financing Needs: The company plans to seek additional funding through public or private equity or debt financings. Failure to secure funding could force delays or elimination of R&D programs.
- Stockholder Rights Plan: In July 2026, the company adopted a stockholder rights plan (poison pill) to deter unsolicited takeover attempts. Rights become exercisable if an acquirer obtains 10% or more of outstanding common stock without board approval.
- Delisting Risk: The company faces potential delisting from Nasdaq under a new Market Value of Listed Securities (MVLS) rule if the market value of its securities remains below $5 million for 30 consecutive business days. The company is currently in discussions with advisors to address compliance.
- Unusual Items: Other income included a $0.3 million refund from the Delaware Secretary of State for overpaid franchise fees.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" regarding going concern status.
- Warrant Dilution: Review the terms of the Class J warrants issued in the recent inducement and the impact of the $1.78 exercise price on future dilution.
- Nasdaq Compliance: Monitor the company's market capitalization and any announcements regarding the MVLS rule stay or compliance plans.
- Rights Plan Impact: Assess how the newly adopted rights plan may affect liquidity and potential M&A activity.
- R&D Milestones: Confirm the status of GEM-AKI and GEM-CKD clinical trials to evaluate the burn rate against potential value creation.